Market-Moving News for July 18th
$AGEN
$BYND
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Packaged Foods
Consumer Staples
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/24/2025 | $2.00 → $1.50 | Underperform | Mizuho | |
| 9/15/2025 | Hold → Sell | Argus | ||
| 8/20/2025 | Underweight | Analyst | ||
| 6/4/2025 | $25.00 | Neutral → Buy | H.C. Wainwright | |
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird | |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | ||
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright | |
| 2/29/2024 | Sell → Hold | Argus |
SCHEDULE 13G/A - BEYOND MEAT, INC. (0001655210) (Subject)
SCHEDULE 13G/A - BEYOND MEAT, INC. (0001655210) (Subject)
SCHEDULE 13D - AGENUS INC (0001098972) (Subject)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
3 - BEYOND MEAT, INC. (0001655210) (Issuer)
Mizuho reiterated coverage of Beyond Meat with a rating of Underperform and set a new price target of $1.50 from $2.00 previously
Argus downgraded Beyond Meat from Hold to Sell
Analyst resumed coverage of Beyond Meat with a rating of Underweight
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - NKGen Biotech, Inc. (0001845459) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab," evaluates how systemic inflammatory markers, tumor microenvironment (TME) immune activity, and peripheral immune cell states are
SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U
Access to Acceleration: Agenus' BOT+BAL Global Momentum Entering 2026 Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus' Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET. The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus' botensilimab and balstilimab (BOT+BAL) program entering 2026. The session will feature perspectives from Agenus leadership and a leading international oncology expert on pr
SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U
SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi
EL SEGUNDO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ:BYND) ("Beyond Meat" or "the Company"), a leader in plant-based meat, today reported financial results for its third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights1 Net revenues were $70.2 million, a decrease of 13.3% year-over-year.Gross profit was $7.2 million, or gross margin of 10.3%, compared to gross profit of $14.3 million, or gross margin of 17.7%, in the year-ago period. Gross profit and gross margin included $1.7 million in expenses related to the suspension and substantial cessation of the Company's operational activities in China. Loss from operations was $112.3 million,
France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on track to commence in fourth quarter 2025 Agenus Inc. (NASDAQ:AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Franc
EL SEGUNDO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- As previously announced, Beyond Meat, Inc. (NASDAQ:BYND) ("Beyond Meat" or "the Company"), a leader in plant-based meat, will host its conference call to discuss its financial results for the third quarter ended September 27, 2025 on Tuesday, November 11, 2025 at 5:00 p.m. Eastern, 2:00 p.m. Pacific. However, the Company announced today that it will now report its financial results for the third quarter ended September 27, 2025 on Monday, November 10, 2025, one day earlier than previously indicated. The adjustment has been made in recognition of the Veterans Day holiday, during which the U.S. Securities and Exchange Commission ("SEC")
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - BEYOND MEAT, INC. (0001655210) (Subject)